REMINDER: HEART TO1 Redemption Period Coming to an end
Press Release 22 February, 2023
February 24 is the last day for trading in warrants of series TO1 in Scandinavian Real Heart AB ("Realheart" or the "Company"). The subscription period for the warrants runs until 28 February 2023. Please note that some trustees will close their registration earlier than 28 February 2023. The last day for trading is Friday 24 February.
For holders who have their warrants registered in a trustee's account, for example in a custody account at a bank, it is important to notify in good time that you wish to exercise your warrants. Realheart recommends that holders who have not received notification from their custodian make contact themselves immediately to avoid the risk of the warrants expiring worthless. Holders should either actively subscribe for shares by 28 February 2023 (note that trustees may have an earlier deadline for response) or sell them via First North by 24 February 2023.
Exercise of warrants, directly registered holders
Directly registered holders of HEART TO1 must notify the exercise of warrants by completing and submitting a special notification form to the issuing institution, Nordic Issuing AB. The notification form must be received by Nordic Issuing AB no later than 28 February 2023. Please note that payment for the new shares must also be received by Nordic Issuing AB no later than 28 February, in accordance with the instructions on the notification form. The subscription form for direct registered holders can be downloaded from Nordic Issuing's website, https://nordic-issuing.se/
Exercise of warrants, nominee-registered holders
Trustee-registered holders of warrants (i.e., for example, if the holding is held in a custody account with a bank or stockbroker) must notify the exercise of warrants by contacting their trustee and following the trustee's instructions regarding notification of subscription and payment. Please note that trustees may have a deadline for replying which falls before the closing date for registration.
Delivery of new shares
The new shares will be delivered to subscribers' accounts as interim shares (HEART IA). They will then be admitted to trading on First North as soon as the issue has been registered with the Swedish Companies Registration Office and Euroclear, which is expected to be in mid-March 2023.
Outcome and delivery of new shares
The outcome of the exercise of the TO1 warrants will be announced via press release as soon as possible and is expected to take place a few days after the end of the subscription period. As soon as the issue has been registered with the Swedish Companies Registration Office and Euroclear, interim shares (IA) will be converted into ordinary shares and admitted to trading on the Nasdaq First North Growth Market.
TO1, terms in brief:
- Four (4) HEART TO1s entitle the holder to subscribe for one (1) newly issued share in Realheart.
- The subscription period for exercise starts on February 1 and ends on February 28, 2023. The last day for trading in the TO1 is February 24, 2023.
- The issue price upon exercise of options is SEK 2.36 per share.
The subscription price was set on 27 January at SEK 2.36 per share in accordance with the option terms, i.e. 70 per cent of the volume-weighted average price during the period.
Full terms and conditions for HEART TO1
The full terms and conditions of HEART TO 1 can be downloaded from www.realheart.se. Warrant exercise instructions and application form are available at www.realheart.se.
Financial advisor and underwriter
Skills Corporate Finance Nordic AB is the financial advisor and Nordic Issuing AB is the issuing agent to Realheart in connection with the exercise of warrants of series TO1.
The warrants, with ISIN code SE0016589246, are traded on Nasdaq First North Growth Market. For more information about the warrants of series TO1, please contact Nordic Issuing.
For more information please contact:
Ina Laura Perkins, CEO
Phone: +46(0)70 406 49 21
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se
Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.